BLUE Stock Price, Bluebird Bio Inc Quote, Chart

Market Summary

USD1.04-0.06

Market Closed

-5.45%

BLUE Stock Price

View Fullscreen

BLUE RSI Chart

BLUE Valuation

Market Cap

113.7M

Price/Earnings (Trailing)

-1.25

Price/Sales (Trailing)

5.23

EV/EBITDA

0.6

Price/Free Cashflow

-0.41

BLUE Price/Sales (Trailing)

BLUE Profitability

Operating Margin

-9.98%

EBT Margin

-419.48%

Return on Equity

-40.97%

Return on Assets

-14.86%

Free Cashflow Yield

-246.78%

BLUE Fundamentals

BLUE Revenue

Revenue (TTM)

21.7M

Rev. Growth (Yr)

17.6K%

Rev. Growth (Qtr)

79.85%

BLUE Earnings

Earnings (TTM)

-91.2M

Earnings Growth (Yr)

6.26%

Earnings Growth (Qtr)

1.61%

Breaking Down BLUE Revenue

Last 7 days

-10.3%

Last 30 days

-26.8%

Last 90 days

-27.3%

Trailing 12 Months

-66.7%

How does BLUE drawdown profile look like?

BLUE Financial Health

Current Ratio

1.55

BLUE Investor Care

Shares Dilution (1Y)

31.87%

Diluted EPS (TTM)

-1.41

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	4.0M	9.4M	21.7M	0
2022	4.7M	6.1M	5.1M	3.6M
2021	189.0M	127.2M	65.4M	3.7M
2020	54.1M	239.7M	250.0M	250.7M
2019	51.1M	56.5M	53.9M	44.7M
2018	44.6M	35.7M	39.5M	54.6M
2017	11.5M	26.7M	32.8M	35.4M
2016	9.2M	5.8M	6.1M	6.2M
2015	25.4M	24.0M	19.0M	14.1M
2014	25.4M	25.4M	25.4M	25.4M
2013	1.4M	7.6M	13.9M	20.2M
2012	0	274.7K	307.3K	340.0K
2011	0	0	0	242.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Bluebird Bio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 04, 2024	klima thomas j	sold	-6,985	1.5276	-4,573	see remarks
Mar 04, 2024	obenshain andrew	sold	-9,310	1.5276	-6,095	president and ceo
Mar 01, 2024	colvin richard a	sold	-10,341	1.5276	-6,770	chief medical officer
Feb 05, 2024	klima thomas j	sold	-2,449	0.9025	-2,714	see remarks
Feb 05, 2024	obenshain andrew	sold	-1,695	0.9025	-1,879	president and ceo
Feb 05, 2024	vittiglio joseph	sold	-4,708	0.9025	-5,217	chief business & legal officer
Jan 05, 2024	obenshain andrew	sold	-4,519	1.4294	-3,162	president and ceo
Jan 05, 2024	colvin richard a	sold	-844	1.415	-597	chief medical officer
Dec 06, 2023	krawtschuk christopher	sold	-20,437	4.5155	-4,526	chief financial officer
Nov 03, 2023	obenshain andrew	sold	-2,554	3.1659	-807	president and ceo

Which funds bought or sold BLUE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	Ausdal Financial Partners, Inc.	new	-	16,017	16,017	-%
Apr 12, 2024	CHANNEL WEALTH LLC	sold off	-100	-17,250	-	-%
Apr 12, 2024	Dynamic Advisor Solutions LLC	added	85.9	36,303	90,026	-%
Apr 10, 2024	Enterprise Bank & Trust Co	new	-	38,400	38,400	0.01%
Apr 09, 2024	Halpern Financial, Inc.	reduced	-40.00	-331	354	-%
Apr 05, 2024	NBC SECURITIES, INC.	new	-	1,000	1,000	-%
Apr 05, 2024	CWM, LLC	added	6.67	-	-	-%
Apr 02, 2024	ST GERMAIN D J CO INC	unchanged	-	-6.00	73.00	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-60.1	-7,393	1,635	-%
Mar 19, 2024	Accent Capital Management, LLC	new	-	4,623	4,623	-%

Are Funds Buying or Selling BLUE?

Are funds buying BLUE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BLUE

No. of Funds

Unveiling Bluebird Bio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	state street corp	1.80%	3,428,135	SC 13G/A
Feb 14, 2024	alyeska investment group, l.p.	6.32%	6,912,502	SC 13G
Feb 14, 2024	pfm health sciences, lp	1.9%	6	SC 13G/A
Feb 14, 2024	tang capital partners lp	0.9%	1,700,000	SC 13G/A
Feb 14, 2024	granahan investment management, llc	7.38%	8,077,697	SC 13G
Feb 13, 2024	vanguard group inc	4.61%	8,775,379	SC 13G/A
Feb 06, 2024	goldman sachs group inc	6.4%	12,181,040	SC 13G
Jan 25, 2024	state street corp	7.28%	13,865,719	SC 13G/A
Jan 08, 2024	blackrock inc.	4.7%	8,983,001	SC 13G/A
Apr 21, 2023	pfm health sciences, lp	5.7%	6	SC 13G

Recent SEC filings of Bluebird Bio Inc

View All Filings

Date Filed	Form Type	Document
Apr 10, 2024	SC 13G/A	Major Ownership Report
Mar 26, 2024	8-K	Current Report
Mar 26, 2024	NT 10-K	NT 10-K
Mar 18, 2024	8-K	Current Report
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Bluebird Bio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	0.01%	-33.89%	-8.42	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.06%	-27.57%	-42.25	10.17	76.23%	61.08%
BMRN	17.3B	2.4B	9.12%	-7.56%	103	7.14	15.42%	18.43%
INCY	12.0B	3.7B	-8.48%	-28.30%	20.07	3.25	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.27%	-36.41%	-11.74	15.65	425.83%	18.94%
BBIO	4.5B	-	-6.46%	74.90%	-6.94	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-9.62%	-0.34%	-13.52	11.95	440.80%	-27.84%
ARWR	3.0B	240.7M	-15.06%	-21.14%	-10.03	12.36	-1.03%	-92.09%
ACAD	2.8B	726.4M	-8.60%	-6.11%	-45.41	3.83	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.17%	-12.95%	25.42	4.56	85.90%	-14.05%
NVAX	576.6M	983.7M	-22.12%	-55.02%	-1.06	0.59	-50.36%	17.16%
CRBP	448.6M	881.7K	-2.13%	345.78%	-10.06	466.16	-77.61%	-5.33%
INO	256.8M	4.9M	2.33%	7.75%	-1.9	52.78	-54.97%	51.72%
IBIO	6.7M	2.1M	82.86%	81.13%	-0.25	2.14	-13.45%	66.37%

Bluebird Bio Inc News

Latest updates

Bluebird Bio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	79.9%	12,392,000	6,890,000	2,381,000	63,000	70,000	1,519,000	1,945,000	1,606,000	1,019,000	143,000	5,425,500	10,708,000	19,273,000	198,890,000	21,863,000	9,997,000	8,910,000	13,296,000	12,471,000	19,243,000	11,528,000
Cost Of Revenue	14.5%	10,955,000	9,564,000	3,376,000	-	-	1,745,000	8,310,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	153.7%	1,437,000	-2,674,000	-995,000	-	71,000	-226,000	-6,365,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Costs and Expenses	4.3%	86,166,000	82,623,000	83,498,000	86,683,000	84,852,000	107,174,000	113,981,000	137,273,000	155,468,000	154,844,000	146,988,000	139,387,000	131,743,000	143,650,000	144,479,000	240,531,000	219,326,000	215,998,000	183,645,000	176,204,000	161,347,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	176,204,000	161,347,000
S&GA Expenses	0.9%	40,703,000	40,349,000	37,354,000	30,706,500	33,402,000	36,694,000	36,106,000	51,196,500	42,229,000	54,984,000	63,569,000	30,028,000	68,046,000	68,628,000	73,248,000	40,684,000	66,250,000	68,631,000	60,279,000	53,508,000	44,527,000
R&D Expenses	7.5%	45,463,000	42,274,000	46,144,000	45,899,500	53,149,000	63,841,000	77,875,000	79,082,000	73,679,000	84,645,000	82,843,000	-131,553,000	140,431,000	156,308,000	154,123,000	-93,473,000	151,412,000	146,540,000	122,640,000	119,722,000	116,744,000
EBITDA Margin	58.8%	-3.99	-9.70	-29.26	-72.69	-82.68	-81.59	-116	-148	-8.40	-4.66	-2.43	-2.16	-	-	-	-	-	-	-	-	-
Income Taxes	100.0%	-	-80,000	-	110,000	7,000	-	-	89,000	-113,000	216,000	66,000	253,000	329,000	10,000	94,000	203,000	-264,000	-469,000	-15,000	-	-
Earnings Before Taxes	1.7%	-71,731,000	-72,988,000	21,240,000	32,342,000	-76,513,000	-100,138,000	-122,152,000	-132,238,000	-152,947,000	-155,757,000	-121,438,000	-141,982,000	-194,416,000	-21,455,000	-202,517,000	11,442,000	-206,297,000	-196,251,000	-164,461,000	-148,836,000	-145,480,000
EBT Margin	58.9%	-4.19	-10.20	-30.52	-74.08	-83.86	-83.34	-119	-153	-8.74	-4.82	-2.54	-2.23	-	-	-	-	-	-	-	-	-
Net Income	1.6%	-71,731,000	-72,908,000	21,240,000	32,232,000	-76,520,000	-100,138,000	-122,152,000	-155,052,000	-216,816,000	-241,702,000	-205,808,000	-199,874,000	-194,745,000	-21,465,000	-202,611,000	-223,347,000	-206,033,000	-195,782,000	-164,446,000	-149,023,000	-145,480,000
Net Income Margin	58.9%	-4.20	-10.20	-30.54	-74.11	-88.30	-97.58	-156	-223	-13.21	-6.62	-3.29	-2.47	-	-	-	-	-	-	-	-	-
Free Cashflow	13.0%	-63,884,000	-73,467,000	-86,870,000	-56,381,000	-78,290,000	-100,337,000	-126,153,000	-141,284,000	-150,679,000	-147,226,000	-210,953,000	-163,081,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	-7.5%	614	663	693	555	520	574	491	594	1,340	1,454	1,637	1,781	1,945	2,108	1,529	1,727	1,892	2,023	2,139	2,243	2,352
Current Assets	-14.2%	247	288	351	199	160	167	255	337	832	904	1,098	1,216	1,293	1,613	967	1,152	1,220	1,301	1,365	1,419	1,725
Cash Equivalents	-4.4%	165	173	239	113	66.00	81.00	106	207	402	353	440	374	324	1,199	347	382	300	281	222	417	952
Inventory	53.7%	21.00	14.00	4.00	-	-	-	-	-	1.00	14.00	18.00	11.00	-	-	-	-	-	-	-	-	-
Net PPE	-2.5%	10.00	10.00	9.00	9.00	12.00	15.00	11.00	10.00	46.00	159	165	17.00	158	155	154	151	144	129	114	247	233
Goodwill	0%	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	12.00	13.00	13.00	6.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00	13.00
Liabilities	4.5%	391	374	338	359	361	393	228	220	469	470	437	426	422	426	409	442	421	387	367	358	351
Current Liabilities	17.7%	159	135	116	128	127	149	143	153	267	248	206	204	197	197	184	224	196	162	147	146	132
Shareholder's Equity	-23.0%	223	289	355	196	159	180	263	374	871	985	1,200	1,355	1,523	1,682	1,120	1,285	1,472	1,636	1,772	1,885	2,001
Retained Earnings	-1.8%	-4,109	-4,038	-3,970	-3,986	-4,020	-3,940	-3,842	-3,719	-3,560	-3,350	-3,106	-2,900	-2,700	-2,505	-2,480	-2,281	-2,058	-1,852	-1,656	-1,498	-1,349
Additional Paid-In Capital	0.1%	4,334	4,328	4,322	4,186	4,181	4,126	4,109	4,096	4,441	4,338	4,311	4,260	4,227	4,190	3,607	3,568	3,533	3,489	3,430	3,387	3,355
Shares Outstanding	0.5%	107	106	106	83.00	82.00	74.00	74.00	71.00	68.00	67.00	67.00	62.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	302	-	-	-	1,399	-	-	-	4,041	-	-	-	7,025	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	15.0%	-61,846	-72,763	-86,600	-56,320	-77,026	-94,358	-125,296	-139,725	-146,939	-145,648	-203,327	-155,193	-148,780	39,743	-206,121	-158,976	-113,381	-137,873	-154,154	-129,731	-74,473
Share Based Compensation	-15.4%	4,868	5,754	5,391	4,679	9,211	8,908	12,390	26,086	28,142	31,160	42,527	32,991	38,818	48,529	36,293	34,631	38,546	55,111	32,341	29,987	29,798
Cashflow From Investing	793.9%	62,083	6,945	82,136	103,242	15,609	61,676	69,926	60,932	119,905	60,368	321,352	148,816	-727,015	269,276	224,578	183,253	129,041	232,426	-36,913	-421,091	33,868
Cashflow From Financing	90.6%	-42.00	-445	130,456	-115	46,325	8,034	9.00	-174,014	75,868	396	3,796	1,432	1,198	543,122	963	2,005	4,178	4,781	10,223	1,921	658,793

BLUE Income Statement

2023-09-30

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue:
Total revenues	$ 12,392	$ 71	$ 21,663	$ 3,534
Cost of product revenue	10,955	0	23,895	10,056
Gross margin	1,437	71	(2,232)	(6,522)
Operating expenses:
Selling, general and administrative	40,703	33,402	118,406	106,201
Research and development	45,463	53,149	133,881	194,864
Restructuring expenses	0	(1,699)	0	4,940
Total operating expenses	86,166	84,852	252,287	306,005
Gain from sale of priority review voucher, net	0	0	92,930	0
Income (loss) from operations	(84,729)	(84,781)	(161,589)	(312,527)
Interest income, net	2,454	383	7,958	663
Other income (expense), net	10,544	7,885	30,152	13,061
Income (loss) before income taxes	(71,731)	(76,513)	(123,479)	(298,803)
Income tax (expense) benefit	0	(7)	80	(7)
Net income (loss)	$ (71,731)	$ (76,520)	$ (123,399)	$ (298,810)
Net income (loss) per share - basic (in dollars per share)	$ (0.66)	$ (0.94)	$ (1.15)	$ (3.91)
Net income (loss) per share - diluted (in dollars per share)	$ (0.66)	$ (0.94)	$ (1.15)	$ (3.91)
Weighted-average number of common shares used in computing net income (loss) per share - basic (in shares)	109,098	81,543	106,924	76,361
Weighted-average number of common shares used in computing net income (loss) per share - diluted (in shares)	109,098	81,543	106,924	76,361
Other comprehensive income (loss):
Total other comprehensive income (loss)	$ 137	$ (214)	$ 1,843	$ (1,719)
Comprehensive income (loss)	(71,594)	(76,734)	(121,556)	(300,529)
Product revenue, net
Revenue:
Revenue	12,281	0	21,414	2,739
Other revenue
Revenue:
Revenue	$ 111	$ 71	$ 249	$ 795

BLUE Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 165,347	$ 113,006
Marketable securities	8,946	67,321
Accounts receivable	23,000	0
Prepaid expenses	11,431	8,374
Inventory	20,969	0
Other current assets	17,383	10,787
Total current assets	247,076	199,488
Marketable securities	0	1,414
Property, plant and equipment, net	9,972	9,362
Goodwill	5,646	5,646
Intangible assets	5,368	4,868
Operating lease right-of-use assets	294,717	281,996
Restricted cash and other non-current assets	50,829	52,128
Total assets	613,608	554,902
Current liabilities:
Accounts payable	19,852	25,092
Deferred revenue	9,653	1,502
Accrued expenses and other current liabilities	57,768	50,483
Operating lease liability, current portion	71,684	51,160
Total current liabilities	158,957	128,237
Operating lease liability, net of current portion	232,023	230,230
Other non-current liabilities	92	92
Total liabilities	391,072	358,559
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.01 par value, 5,000 shares authorized; 0 shares issued and outstanding at September 30, 2023 and December 31, 2022	0	0
Common stock, $0.01 par value, 250,000 shares authorized; 107,022 and 82,923 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	1,071	830
Additional paid-in capital	4,333,594	4,186,086
Accumulated other comprehensive loss	(2,227)	(4,070)
Accumulated deficit	(4,109,902)	(3,986,503)
Total stockholders’ equity	222,536	196,343
Total liabilities and stockholders’ equity	$ 613,608	$ 554,902

About Bluebird Bio Inc

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ÃƒÅ¸-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ÃƒÅ¸-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

CEO	Mr. Andrew Obenshain
WEBSITE	bluebirdbio.com
INDUSTRY	Biotechnology
EMPLOYEES	323

Bluebird Bio Inc Frequently Asked Questions

What is the ticker symbol for Bluebird Bio Inc? What does BLUE stand for in stocks?

BLUE is the stock ticker symbol of Bluebird Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bluebird Bio Inc (BLUE)?

As of Mon Apr 15 2024, market cap of Bluebird Bio Inc is 113.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BLUE stock?

You can check BLUE's fair value in chart for subscribers.

What is the fair value of BLUE stock?

You can check BLUE's fair value in chart for subscribers. The fair value of Bluebird Bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bluebird Bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BLUE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bluebird Bio Inc a good stock to buy?

The fair value guage provides a quick view whether BLUE is over valued or under valued. Whether Bluebird Bio Inc is cheap or expensive depends on the assumptions which impact Bluebird Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BLUE.

What is Bluebird Bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, BLUE's PE ratio (Price to Earnings) is -1.25 and Price to Sales (PS) ratio is 5.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BLUE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Bluebird Bio Inc's stock?

In the past 10 years, Bluebird Bio Inc has provided -0.256 (multiply by 100 for percentage) rate of return.